PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)

Clinical trials for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) explained in plain language.

Never miss a new study

Get alerted when new PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) trials appear

Sign up with your email to follow new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 4 Not yet recruiting 1 Not yet finished but already full! 2

Alpelisib's Long-Term safety tracked in PIK3CA patients

Disease control Not yet recruiting

This study provides continued access to alpelisib for people who are already benefiting from it in a previous Novartis trial. It focuses on tracking long-term safety, including any side effects, in participants with PIK3CA-related overgrowth spectrum or certain breast cancers. Pa…

Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)

Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Jul 02, 2026 02:00 UTC

PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)

Get alerted when new PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) trials appear

Alpelisib's Long-Term safety tracked in PIK3CA patients